Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

This episode includes major insights from around the biopharma world for the business week ended 8 January 2021.

This week, we take a look at a high-profile corporate logo change, further coronavirus vaccine developments, major drug launches last year despite the pandemic, and what one Japanese firm has been doing to cope with the new normal. 

These podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Play, SoundCloud and TuneIn and via smart speakers if one of these channels has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "Pfizer Bids Farewell To Blue Pill With New Double Helix Logo" - Scrip, 6 Jan, 2021.)

(Also see "UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts" - Scrip, 30 Dec, 2020.)

(Also see "First In World COVID-19 Vaccine For Kids Below 12?" - Scrip, 6 Jan, 2021.)

(Also see "2020 Drug Launches, Like Everything, Will Be Remembered For COVID-19" - Scrip, 2 Jan, 2021.)

(Also see "Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko" - Scrip, 4 Jan, 2021.)

 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC143606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel